Stay updated with breaking news from Sight Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neurology journal BRAIN publishes efficacy and safety results at 1.5-year post treatment BMJ1 Open Ophthalmology publishes characteristics of the ND4-LHON study population before treatment Regulatory
The credit facility will enable GenSight to support the development of its pipeline and in particular the preparation of the marketing of LUMEVOQ in Europe The credit facility consists of
EMA D120 Responses submitted in October as planned Two successful engineering batches of LUMEVOQ validate actions taken to correct low yields in previous runs €13.9 million of cash
Philippe Motté as Senior VP, Regulatory and QualityMichiel Hemels as VP, Global Pricing and Market AccessPARIS--(BUSINESS WIRE)--Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for reti...
Ramp up of sales marketing actions and investments to drive commercial launch of LUMEVOQ in Europe in 2023 Cash runway confirmed to early Q1 2023 Advanced discussions on refinancing